UBS Maintains a 'Buy' on Cisco (CSCO); Strong 2Q Execution, Outperforming Comps
Tweet
Share
E-mailGet Alerts CSCO Hot Sheet
Price: $109.72 -0.75%
Rating Summary:
35 Buy, 27 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 20
Rating Summary:
35 Buy, 27 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 20
Join SI Premium – FREE
UBS maintains a 'Buy' on Cisco (NASDAQ: CSCO) price target raised from $23 to $24.
UBS analyst says, "2Q revs and EPS beat investor expectations. Cisco’s order pipeline was healthy growing 7% YoY with a B2B of 1...CSCO again defied service provider capital spending gravity with total SP orders +12% YoY, leading customer order growth for the 3rd quarter running."
"We tweak our CY12 and CY13 sales and EPS fcsts higher to $47.4B (+6%) and $1.87 and $50.8B (+7%) and $2.02 from $46.5B and $1.81 and $49.9B and $1.96. Cisco generated $2.8B in FCF in 2Q, raised its qtrly dividend to $0.08 per shr, and we expect M&A to become a new priority. Total cash of ~$46.7B (~$5B in US)."
For an analyst ratings summary and ratings history on Cisco click here. For more ratings news on Cisco click here.
Shares of Cisco closed at $20.43 yesterday.
UBS analyst says, "2Q revs and EPS beat investor expectations. Cisco’s order pipeline was healthy growing 7% YoY with a B2B of 1...CSCO again defied service provider capital spending gravity with total SP orders +12% YoY, leading customer order growth for the 3rd quarter running."
"We tweak our CY12 and CY13 sales and EPS fcsts higher to $47.4B (+6%) and $1.87 and $50.8B (+7%) and $2.02 from $46.5B and $1.81 and $49.9B and $1.96. Cisco generated $2.8B in FCF in 2Q, raised its qtrly dividend to $0.08 per shr, and we expect M&A to become a new priority. Total cash of ~$46.7B (~$5B in US)."
For an analyst ratings summary and ratings history on Cisco click here. For more ratings news on Cisco click here.
Shares of Cisco closed at $20.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Eclat Textile Co Ltd (1476:TT) PT Lowered to NT$547 at Macquarie
- Oppenheimer Reiterates Outperform Rating on NVIDIA (NVDA) Into EPS
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBS, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
